Stock Research for ACRX

ACRX

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

ACRX Stock Chart & Research Data

The ACRX chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the ACRX chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


ACRX Due diligence Resources & Stock Charts

The ACRX stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View ACRX Detailed Price Forecast - CNN Money CNN View ACRX Detailed Summary - Google Finance
Yahoo View ACRX Detailed Summary - Yahoo! Finance Zacks View ACRX Stock Research & Analysis - Zacks.com

Stock Analysis

TradeIdeas View ACRX Trends & Analysis - Trade-Ideas Barrons View ACRX Major Holders - Barrons
NASDAQ View ACRX Call Transcripts - NASDAQ Seeking View ACRX Breaking News & Analysis - Seeking Alpha
Spotlight View ACRX Annual Report - CompanySpotlight.com OTC Report View ACRX OTC Short Report - OTCShortReport.com
TradeKing View ACRX Fundamentals - TradeKing Charts View ACRX SEC Filings - Bar Chart
WSJ View Historical Prices for ACRX - The WSJ Morningstar View Performance/Total Return for ACRX - Morningstar
MarketWatch View the Analyst Estimates for ACRX - MarketWatch CNBC View the Earnings History for ACRX - CNBC
StockMarketWatch View the ACRX Earnings - StockMarketWatch MacroAxis View ACRX Buy or Sell Recommendations - MacroAxis
Bullish View the ACRX Bullish Patterns - American Bulls Short Pains View ACRX Short Pain Metrics - ShortPainBot.com

Social Media Mentions

StockTwits View ACRX Stock Mentions - StockTwits PennyStocks View ACRX Stock Mentions - PennyStockTweets
Twitter View ACRX Stock Mentions - Twitter Invest Hub View ACRX Investment Forum News - Investor Hub
Yahoo View ACRX Stock Mentions - Yahoo! Message Board Seeking Alpha View ACRX Stock Mentions - Seeking Alpha


Financial & Transaction Holdings

SECform4 View Insider Transactions for ACRX - SECform4.com Insider Cow View Insider Transactions for ACRX - Insider Cow
CNBC View ACRX Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for ACRX - OTC Markets
Yahoo View Insider Transactions for ACRX - Yahoo! Finance NASDAQ View Institutional Holdings for ACRX - NASDAQ


Stock Charts

FinViz View ACRX Stock Insight & Charts - FinViz.com StockCharts View ACRX Investment Charts - StockCharts.com
BarChart View ACRX Stock Overview & Charts - BarChart Trading View View ACRX User Generated Charts - Trading View




Latest Financial News for ACRX


Concert Pharma's CTP-692 Positive for Schizophrenia in Phase I
Posted on Thursday June 13, 2019

Concert Pharma (CNCE) reports favorable data from the two early-stage studies on its pipeline candidate, CTP-692, currently under evaluation as an adjunctive treatment for schizophrenia. Share rise.


Edited Transcript of ACRX earnings conference call or presentation 8-May-19 8:30pm GMT
Posted on Thursday June 06, 2019

Q1 2019 AcelRx Pharmaceuticals Inc Earnings Call


AcelRx announces the closing of a $25 million senior secured debt facility
Posted on Monday June 03, 2019

REDWOOD CITY, Calif., June 3, 2019 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced the closing of a $25 million senior secured debt facility with Oxford Finance LLC, a specialty finance firm providing senior debt to life sciences and healthcare services companies worldwide. "We are pleased to announce the closing of this debt financing with Oxford," said Vince Angotti, AcelRx Chief Executive Officer.


AcelRx Pharmaceuticals (ACRX) Upgraded to Buy: Here's Why
Posted on Friday May 17, 2019

AcelRx Pharmaceuticals (ACRX) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.


Stock Market & Investing Books

Enter a stock symbol to view the stock details.